---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008242"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:03:13.538889+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma reports FY2022 net loss $14.3M; cash $55.2M; IND timeline for LP-184/LP-284 in 2023

## Summary
- FY2022 net loss $14.3M ($1.31/sh) vs $12.4M ($1.13/sh) in FY2021; cash and equivalents $55.2M (Dec 31, 2022) down from $70.7M.
- IND submission for LP-184 expected April 2023; LP-284 IND and first-in-human Phase 1 trials targeted for mid-2023.
- Phase 2 Harmonic trial (LP-300) activated 5 sites across 12 US locations; first patient dosing anticipated Q2 2023.
- Formed wholly-owned subsidiary Starlight Therapeutics for CNS cancers; STAR-001 clinical trials planned for late 2023/early 2024.
- RADR platform surpassed 25 billion oncology datapoints; target of 50 billion in coming year; cash runway into 2025.

## SEC filing metadata
- accession: 0001493152-23-008242
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/0001493152-23-008242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008242
- JSON: https://secwatch.observer/filing/0001493152-23-008242.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008242.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 20, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31 , 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/0001493152-23-008242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.